INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 140 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2017. The put-call ratio across all filers is 1.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,786,000 | +6.9% | 146,671 | 0.0% | 0.02% | -4.2% |
| Q4 2018 | $1,671,000 | -61.2% | 146,671 | -26.2% | 0.02% | -56.4% |
| Q3 2018 | $4,312,000 | +40.5% | 198,703 | +14.4% | 0.06% | +27.9% |
| Q2 2018 | $3,069,000 | +6.1% | 173,656 | +26.4% | 0.04% | -2.3% |
| Q1 2018 | $2,892,000 | -10.2% | 137,403 | -38.2% | 0.04% | -6.4% |
| Q4 2017 | $3,222,000 | -15.7% | 222,510 | -8.1% | 0.05% | -13.0% |
| Q3 2017 | $3,821,000 | +41.2% | 242,156 | +11.1% | 0.05% | +31.7% |
| Q2 2017 | $2,707,000 | -11.3% | 217,962 | +16.0% | 0.04% | -21.2% |
| Q1 2017 | $3,052,000 | +110.6% | 187,823 | +95.6% | 0.05% | +85.7% |
| Q4 2016 | $1,449,000 | +40.8% | 96,048 | +42.3% | 0.03% | +55.6% |
| Q3 2016 | $1,029,000 | -85.7% | 67,500 | -63.6% | 0.02% | -87.0% |
| Q2 2016 | $7,201,000 | +106.4% | 185,500 | +47.8% | 0.14% | +106.0% |
| Q1 2016 | $3,489,000 | -47.7% | 125,500 | +1.2% | 0.07% | -42.7% |
| Q4 2015 | $6,670,000 | – | 124,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |